Skin Cancer

Thazin Aung, PhD, discusses AI's role in standardizing immune cell evaluation in melanoma, enhancing diagnostic consistency and clinical decision-making.

Medicus Pharma has initiated a phase 2 trial in the UAE for a non-invasive BCC treatment, aiming to revolutionize skin cancer care.

Greater awareness of UV risks and stricter sun protection have contributed to declining invasive melanoma rates.

COVID-19 significantly delayed melanoma diagnoses and treatments, leading to increased disease severity and advanced cases, highlighting urgent health care needs.

While survival rates were similar across income levels, lower-income patients consistently presented with more aggressive disease.

The FDA cited concerns about patient population heterogeneity and confirmatory trial design.

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

The test now provides 3 validated insights: risk of metastasis, response to ART, and risk of recurrence.

A case report presents a unique case of Bowen's disease affecting the lower extremities in a 75-year-old woman, which was initially misdiagnosed as a fungal infection.

Irina Mazur spoke to Dermatology Times about the latest partnership, which aims to bridge the gap between clinical advice and patient behavior through personalized sun protection guidance.

Merck's pembrolizumab gains Health Canada approval for innovative perioperative treatment of advanced head and neck squamous cell carcinoma, enhancing patient outcomes.

Immutep advances eftilagimod alfa for head and neck squamous cell carcinoma, targeting patients with low PD-L1 expression and limited treatment options.

New clinical trial results reveal that intratumoral vidutolimod combined with pembrolizumab shows promise for treating advanced melanoma resistant to PD-1 therapy.

Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.

Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.

Anisha Patel, MD, highlights dermatology's vital role in cancer care, discussing skin indicators and innovative immunotherapy at her Elevate-Derm Summer sessions.

Ata Moshiri, MD, MPH, FAAD, spoke about pathology interpretation and patient communication at Elevate-Derm Summer 2025, enhancing skin cancer diagnosis.

Discover how gene expression profiling transforms melanoma and SCC management, enhancing personalized treatment strategies and improving patient outcomes in skin cancer care.

Castle Biosciences’ DecisionDx-Melanoma test plays a role in melanoma management with precise risk stratification, enhancing patient outcomes and reducing unnecessary surgeries.

Replimune faces FDA challenges for RP1's approval in advanced melanoma, highlighting complexities in cancer drug development and regulatory scrutiny.

This review of the latest dermatologic studies includes insights into ocular safety during laser procedures, radiation dermatitis prevention and management, and more.

Melanoma survivors share their diagnoses and advocate for early detection, routine skin exams, and public education to save lives.

At a recent Dermatology Times Case-Based Roundtable event, Gaurav Singh, MD, MPH, FAAD, FACMS, utilized 3 patient cases to explore the role of GEP testing in melanoma and SCC.

This review of the latest dermatologic studies includes insights into immunomodulatory effects of photodynamic therapy for skin cancer, in vivo and ex vivo sonographic evaluation of tumor margins, and more.